{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:16Z","timestamp":1792269676616,"version":"4.4.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"\n Background<\/jats:title>\n Albendazole is a widely used broad-spectrum anthelmintic whose recognized neuropsychiatric adverse effects are largely limited to encephalitis and demyelinating encephalopathy. Panic attack has not been previously reported as an adverse reaction to albendazole.<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n \n A 59-year-old Chinese man with recent percutaneous coronary intervention for coronary artery disease was prescribed albendazole (600 mg\/day for 7 days) for an incidentally detected\n Clonorchis sinensis<\/jats:italic>\n infection. Within hours of his first dose, he developed recurrent, unpredictable panic attacks characterized by palpitations, chest pain, dyspnea, derealization, fear of dying, and a sense of losing control. These episodes met DSM-5 diagnostic criteria for panic attack (11 of 13 core symptoms) and were graded as Grade 2 according to the Common Terminology Criteria for Adverse Events version 5.0. Extensive cardiac, pulmonary, and psychiatric workup excluded alternative causes. The panic attacks resolved following albendazole discontinuation and combination anxiolytic\u2013antidepressant therapy. The Naranjo adverse drug reaction probability score was 8, indicating a probable causal relationship.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This case suggests that albendazole can probably induce acute panic attacks, expanding its neuropsychiatric adverse effect spectrum. In patients with heightened central nervous system vulnerability\u2014such as those recovering from major cardiovascular procedures\u2014the risk may be increased. For non-urgent anthelmintic indications in such patients, deferring treatment until clinical stabilization may be prudent.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1915974","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:35:39Z","timestamp":1787895339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Panic attack induced by albendazole in a post-PCI patient"],"prefix":"10.3389","volume":"17","author":[{"given":"Rijian","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, People's Hospital of Guangxi Zhuang Autonomous Region (Guangxi Academy of Medical Sciences)","place":["Nanning, Guangxi, China"]},{"name":"School of Pharmacy, Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, People's Hospital of Guangxi Zhuang Autonomous Region (Guangxi Academy of Medical Sciences)","place":["Nanning, Guangxi, China"]},{"name":"Department of Pharmacy, Ping Guo People\u2019s Hospital","place":["Baise, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, People's Hospital of Guangxi Zhuang Autonomous Region (Guangxi Academy of Medical Sciences)","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1017\/s0031182000007290","article-title":"Albendazole: a review of anthelmintic efficacy and safety in humans","volume":"121","author":"Horton","year":"2000","journal-title":"Parasitology"},{"key":"B2","article-title":"Albendazole","volume-title":"Statpearls","author":"Mamidi","year":"2025"},{"key":"B3","volume-title":"ALBENZA (Albendazole) Tablets [prescribing information]","year":"2024"},{"key":"B4","first-page":"3","article-title":"Levamisole, mebendazole, albendazole and encephalitis syndrome","year":"2003","journal-title":"WHO Pharm Newslett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2017.02.008","article-title":"Drug-induced panic attacks: analysis of cases registered in the French pharmacovigilance database","volume":"90","author":"Abadie","year":"2017","journal-title":"J Psychiatr Res"},{"key":"B6","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B7","volume-title":"Common Terminology Criteria for Adverse Events (Ctcae) Version 5.0","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1139\/jpn.0525","article-title":"Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder","volume":"30","author":"Zwanzger","year":"2005","journal-title":"J Psychiatry Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0563-04.2004","article-title":"Variability in the benzodiazepine response of serotonin 5-HT1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABA(A) receptors","volume":"24","author":"Bailey","year":"2004","journal-title":"J Neurosci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-08-02758.2000","article-title":"Genetic inactivation of the serotonin 1A receptor in mice results in downregulation of major GABA(A) receptor \u03b1 subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety","volume":"20","author":"Sibille","year":"2000","journal-title":"J Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/trstmh\/try023","article-title":"The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis","volume":"112","author":"Thapa","year":"2018","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.9740\/mhc.2019.11.397","article-title":"Case report: Albendazole associated psychosis","volume":"9","author":"Doughty","year":"2019","journal-title":"Ment Health Clin"},{"key":"B14","doi-asserted-by":"publisher","first-page":"578.e9","DOI":"10.1016\/j.genhosppsych.2012.01.009","article-title":"Drug-induced psychosis associated with albendazole\u2013ivermectin combination therapy","volume":"34","author":"Sinha","year":"2012","journal-title":"Gen Hosp Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1915974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:35:41Z","timestamp":1787895341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1915974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":14,"alternative-id":["10.3389\/fpsyt.2026.1915974"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1915974","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1915974"}}